The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Should bevacizumab (B) be included in the first-line treatment of elderly patients with advanced colorectal cancer (CRC)? Results from a community-based Italian observational study.
Stefania Eufemia Lutrino
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Lorenzo Calvetti
No relevant relationships to disclose
Gerardo Rosati
No relevant relationships to disclose
Riccardo Giampieri
No relevant relationships to disclose
Antonio Avallone
No relevant relationships to disclose
Stefano Sergio Cordio
No relevant relationships to disclose
Massimiliano Berretta
No relevant relationships to disclose
Fabiola Lorena Rojas Llimpe
No relevant relationships to disclose
Luisa Foltran
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Mario Scartozzi
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Carmine Pinto
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Roche
Honoraria - Roche
Stefano Cascinu
No relevant relationships to disclose
Roberto Bordonaro
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Gianpiero Fasola
No relevant relationships to disclose
Giuseppe Aprile
Honoraria - Roche